Treatment of ocular inflammatory conditions with loteprednol etabonate

@article{Pavesio2008TreatmentOO,
  title={Treatment of ocular inflammatory conditions with loteprednol etabonate},
  author={Carlos E Pavesio and Heleen H DeCory},
  journal={British Journal of Ophthalmology},
  year={2008},
  volume={92},
  pages={455 - 459}
}
Ocular inflammatory diseases impose a significant medical and economic burden on society. Corticosteroids are potent anti-inflammatory agents that have been used successfully to treat ocular inflammation. Topical corticosteroids provide maximal drug delivery, and are used to reduce the signs and symptoms of intraocular and ocular surface inflammation. However, side effects associated with topical corticosteroids—including increased intraocular pressure, risk of cataract formation after long… 
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
TLDR
The cumulative data to date substantiates a favorable IOP-safety profile for LE with both short-term and long-term use, and indicates use of LE was associated with significantly lower rates of IOP elevation as compared to prednisolone acetate or dexamethasone (when used in combination with tobramycin).
Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens
TLDR
LE/T may be a safer treatment option for ocular inflammation in which there is risk of superficial bacterial infections, and studies with either LE or LE/T indicate that LE has a lower risk of IOP elevation compared with C-20 ketone corticosteroids.
Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
TLDR
The available clinical data suggest that loteprednol etabonate is an efficacious and safe corticosteroid for the treatment of postoperative inflammation.
Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis
TLDR
The development of modified or soft, smart corticosteroids such as loteprednol etabonate provides an avenue for expanding the treatment of the inflammation associated with signs and symptoms in patients with chronic forms or severe acute exacerbations of allergic conjunctivitis.
Ocular surface disease: a case of vernal keratoconjunctivitis.
Topical Corticosteroids and Antihistamines—Mast Cell Stabilizers for the Treatment of Allergic Conjunctivitis
TLDR
The most common ocular manifestation of allergy, allergic conjunctivitis (ac), is the result of a hypersensitivity response occurring after exposure of the ocular surface to airborne antigens and corticosteroids offer the most complete option for ac, although their use has been limited due to concerns about increased intraocular pressure and the potential for cataract formation with extended use.
Topical Steroids in Management of Dry Eye Disease
TLDR
Topical steroids have proven beneficial in conjunction with other anti-inflammatory medications such as topical calcineurin inhibitors, and as inflammation plays an important role in pathogenesis of DED, topical steroids may be considered for patients with refractory disease.
Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
TLDR
Results of published studies indicate that LE/T is effective in the treatment of blepharokeratoconjunctivitis in adults, with similar efficacy as dexamethasone 0.1%/tobramycin 0.3%, but is associated with a lower risk of clinically significant increases in intraocular pressure.
Efficacy and safety comparison of topical loteprednol and topical non-steroidal anti-inflammatory drugs in seasonal allergic conjunctivitis: a prospective open label comparative study
TLDR
SAC the topical steroid loteprednol was found superior to NSAIDs, and only ketorolac comparable to lotepednol in relieving ocular itching.
Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?
TLDR
The proportion of patients exhibiting an increase of ≥10 mmHg IOP in clinical studies has emerged as the most clinically relevant parameter for ophthalmologists to consider when deciding on which topical corticosteroid to use.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Loteprednol etabonate: a review of ophthalmic clinical studies.
TLDR
Loteprednol etabonate (LE) is a corticosteroid designed using the "soft drug" concept of Bodor which has a superior safety profile which has been attributed to its " soft drug" characteristics.
Antiinflammatory therapy for dry eye.
Loteprednol etabonate: a review of ophthalmic clinical studies.
TLDR
Loteprednol etabonate (LE) is a corticosteroid designed using the "soft drug" concept of Bodor which has a superior safety profile which has been attributed to its " soft drug" characteristics.
Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
TLDR
LE was well tolerated and was clinically effective for the treatment of GPC, and ratings for bulbar conjunctival injection and the Patient Opinion Assessment demonstrated statistical trends that favored treatment with LE.
Soft steroids: a new approach to the treatment of inflammatory airways diseases.
Comparison of topical steroids for acute anterior uveitis.
TLDR
All steroid treatments reduced uveitis to some degree but LE was consistently effective and a longer observation period may be required to document the return of IOP and corneal thickness to baseline values.
Intraocular pressure response to loteprednol etabonate in known steroid responders.
TLDR
LE has less effect on IOP when compared to the IOP response induced by PA, and LE may become a clinically useful ocular steroid with a favorable IOP-safety profile.
Management of sight-threatening uveitis: new therapeutic options.
TLDR
This paper primarily summarises literature from the past 5 years, gives an update on systemic immunosuppressive therapy for non-infectious uveitis and speculates about new developments that could become relevant in the near future.
Ocular allergic disease
TLDR
This review will focus on recent advances in the understanding of the pathogenesis of allergic eye diseases and how complex interactions and cross talk between cells, cytokines and other mediators is relevant for new therapeutic approaches directed at specific disease entities.
...
1
2
3
4
5
...